Location
Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Overview:
Duchenne muscular dystrophy is a genetic disorder which causes progressive muscle degeneration and weakness, and it is one of the nine types of muscular dystrophy. Duchenne muscular dystrophy mostly affects males, but in rare cases occurs in females. Onset of the disease is generally 3 to 4 years of age and begins on hips, pelvic region, shoulders, and upper legs. Symptoms may include delayed or difficulty inability to stand, walk and difficulty in speaking.
Disease is diagnosed through the patient history, blood test for creatinine phosphokinase levels, molecular genetic testing, and muscle biopsy. There is no cure available for the disease till now. But the medications are available forrelieving the symptoms of the disease. Eteplirsen is used to treat the patients with specific gene mutation of gene that leads to DMD. Deflazacort, approved in 2017, becoming first corticosteroid to treat Duchenne muscular dystrophy.
Segmentation:
By formulation, Duchenne muscular dystrophy pipeline drugs are segmented into
By therapy, Duchenne muscular dystrophy pipeline drugs are segmented into
By trial phase, Duchenne muscular dystrophy pipeline drugs are segmented into
By company, Duchenne muscular dystrophy pipeline drugs are segmented into
Space Analysis:
Until the approval of exon skipping agent eteplirsen, carticostroids are the only potential treatment for the treatment of duchenne muscular atrophy, but with many side effects. Duchenne muscular dystrophy pipeline has the robust drug molecules and therapies such as gene therapy, exon skipping agents and also promising corticosteroids for the treatment. Furthermore, Catabasis Pharmaceuticals has been developing NF-kB protein inhibitor in phase-II development to treat duchenne muscular dystrophy. Moreover, there are numerous early stage development of drugs including, drugs which targets calcium regulation, fibrosis and oxidative stress.
Â
Report Description:
Duchenne Muscular Dystrophy Pipeline Drugs Assessment report studies the various therapeutics under clinical development for XYX treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Duchenne muscular dystrophy pipeline drugsdevelopment. This report studies the dynamics of the Duchenne Muscular Dystrophy Pipeline Drugs i.e. drivers, challenges,andopportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Duchenne muscular dystrophy pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Key Features of the Report:
Location
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Â
Disclaimer
The above mentioned segmentation is tentative; it is changed according to client’s requirement, or research feasibility.
Â